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Summary. This article introduces methods for use in vaccine clinical trials to help determine whether the
immune response to a vaccine is actually causing a reduction in the infection rate. This is not easy because
immune response to the (say HIV) vaccine is only observed in the HIV vaccine arm. If we knew what the
HIV-speciﬁc immune response in placebo recipients would have been, had they been vaccinated, this immune
response could be treated essentially like a baseline covariate and an interaction with treatment could be
evaluated. Relatedly, the rate of infection by this baseline covariate could be compared between the two
groups and a causative role of immune response would be supported if infection risk decreased with increasing
HIV immune response only in the vaccine group. We introduce two methods for inferring this HIV-speciﬁc
immune response. The ﬁrst involves vaccinating everyone before baseline with an irrelevant vaccine, for
example, rabies. Randomization ensures that the relationship between the immune responses to the rabies
and HIV vaccines observed in the vaccine group is the same as what would have been seen in the placebo
group. We infer a placebo volunteer’s response to the HIV vaccine using their rabies response and a prediction
model from the vaccine group. The second method entails vaccinating all uninfected placebo patients at
the closeout of the trial with the HIV vaccine and recording immune response. We pretend this immune
response at closeout is what they would have had at baseline. We can then infer what the distribution of
immune response among placebo infecteds would have been. Such designs may help elucidate the role of
immune response in preventing infections. More pointedly, they could be helpful in the decision to improve
or abandon an HIV vaccine with mediocre performance in a phase III trial.
Key words: AIDS; Causal inference; Correlate of protection; Counterfactual; HIV; Missing data; Principal
stratiﬁcation; Surrogate endpoint.
1. Introduction
A vaccine contains innocuous material that provokes a re-
sponse by the adaptive immune system. Following vacci-
nation, the immune system mounts a multifaceted, and
exquisitely speciﬁc, counterattack based on two types of white
blood cells, B-lymphocytes and T-lymphocytes. These cells
respond to speciﬁc proteins of the vaccine material, prolifer-
ate, and wait to subsequently attack either ﬂoating microbes
or infected cells that display such peptides. B-lymphocytes
produce antibodies that recognize proteins in the outer sur-
face of the virus and neutralize their ability to infect cells.
T-lymphocytes produce cells that either kill or aid in killing
infected cells. The magnitude of each component of the adap-
tive immune response to the vaccine can be measured. Vac-
cine development focuses on inducing a strong, measurable
immune response while ensuring that the vaccine is safe (see,
e.g., Halloran, 1998; Nabel, 2001; or Chan, Wang, and Heyse,
2003).
Establishing the role of vaccine-induced immune response
on actual protection of infection and disease is an important
open problem in vaccine studies (Halloran, 1998). A “cor-
relate of protection” is the threshold for immune response,
say xp, beyond which infections and disease do not occur
(Lachenbruch et al., 2000). Methods for estimating such a
threshold are discussed in Carey, Barker, and Platt (2001),
Chan et al. (2002), and Plikaytis and Carlone (2005). How-
ever, when immune response only occurs in the vaccinated
group, validation of a correlate of protection, or more gener-
ally validation of immune response as a true surrogate with
a causative role, is problematic (Chan et al., 2003). The use
of Prentice’s criteria to establish surrogacy, conditional in-
dependence of treatment, and outcome given the surrogate
(Prentice, 1989) breaks down here because immune response
to the vaccine basically only occurs in the vaccine group and
thus the value of the surrogate basically identiﬁes the treat-
ment group. Strictly speaking, one cannot know whether the
measured immune responses, or other unmeasured vaccine-
induced changes, are actually responsible for an eﬃcacious
vaccine. For example, it could be that those individuals who
achieve xp in response to a weak vaccine are more intrinsi-
cally ﬁt than others so that even if a more powerful vaccine
achieved xp in everyone, not all would be protected.
That this might be an actual problem was demonstrated in
VAX004, the ﬁrst phase III trial of an HIV vaccine (Gilbert
et al., 2005; The rgp120 HIV Vaccine Study Group, 2005).
Overall, the vaccine was not eﬀective, with infection rates
of 0.067 and 0.070, respectively, in the vaccine and placebo
groups based on 5403 volunteers. However, the antibody re-
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Table 1
The relative hazard of infection, based on a Cox model, as a
function of antibody response to the HIV vaccine, which is
only measured in the vaccine group. It seems the
vaccine-induced antibodies are doing their job.
Quartile of antibody response
following HIV vaccination
Group Weak Modest Good Best
Vaccine 1.00 0.35∗ 0.28∗ 0.22∗
∗p < 0.05.
sponse to the HIV vaccine was strongly associated with in-
fection risk in the vaccine group. Tables 1 and 2 provide
the relative hazard of infection as a function of antibody
response quartiles, ﬁrst within the vaccine group and then
when the placebo group is used as a control (see Gilbert
et al., 2005). Because antibody response to the HIV vac-
cine is only measured in the vaccine group, Table 2 has
question marks in the placebo cells—we do not know what
HIV immune response they would have had, had they been
vaccinated.
Two hypotheses were postulated to explain these results
(Gilbert et al., 2005; Graham and Mascola, 2005). The ﬁrst
was that antibody response is identifying volunteers with dif-
ferent constitutional ability to avoid infection but the vaccine-
induced immune response had no causative role. We call this
the association hypothesis. The second was that the vaccine
caused infections in those with the weakest immune response
and prevented infections in those with the strongest immune
response. We call this the causation hypothesis. As it stands,
neither of these hypotheses can be evaluated on the basis of
data.
In this article we introduce two new designs to help under-
stand the role of immune response in vaccines. These designs
can discriminate between the two hypotheses outlined above.
The ﬁrst design is to inoculate everyone in both arms prior
to randomization with an irrelevant vaccine, say rabies. We
call this baseline irrelevant vaccination (BIV), and let W0 be
the immune response to the rabies vaccine at baseline. Also,
Table 2
When we calculate the relative hazard for the four quartiles
compared to the placebo group, a diﬀerent picture emerges
(Gilbert et al., 2005). The numbers provide the hazard relative
to the overall placebo group, while the ?’s emphasize that
immune response following HIV vaccination is not measurable
in the placebo group and thus the relative hazards
are unknown.
Quartile of antibody response
following HIV vaccination
Group Weak Modest Good Best Overall
Placebo ? ? ? ? 1.00
Vaccine 1.86∗ 0.99 0.99 0.81
∗p < 0.05.
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Figure 1. Made-up scatterplot illustrating imputation of
the immune response to an HIV vaccine (X0) in the placebo
group based on the observed immune response to a rabies
vaccine (W0) for a single patient. The bivariate distribution
between X0, W 0 is observed in the vaccine group. Random-
ization assures that this distribution and regression line also
apply to the placebo group. While X0 cannot be observed in
the placebo group, W0 can and provides the basis for impu-
tation. A very high correlation between X0, W 0 is used to
illustrate the concept.
we deﬁne X0 as the immune response to the HIV vaccine,
which is measured just after randomization in the vaccine
group. Randomization ensures that the relationship between
W 0, X0 observed in the vaccine group is the same in the
placebo group. Based on this relationship, the observed W0
of a placebo participant can be used to infer his X0. Figure 1
illustrates how W0 can be used to impute X0 in the placebo
group when they are very highly correlated (ρ = 0.98). It
is important to note that a rabies vaccine is not required—
any baseline measurement that correlated well with X0 would
work, but an irrelevant vaccination is a good choice. This
type of thinking to predict a post-randomization characteris-
tic only observed in the treatment group has been used before
in heart disease (see, e.g., Follmann, 2000, or Hallstrom et al.,
2001).
The second way to get at X0 in the placebo group would
be to vaccinate all the uninfected placebo recipients at the
closeout of the trial with the HIV vaccine and then measure
their immune response, say XC. If we make the assumption
that XC is the same as X0, we eﬀectively obtain X0 in many.Augmented Designs to Assess Immune Response in Vaccine Trials 1163
Table 3
Hypothetical data set of a trial where 800 patients are
randomized. The vaccine group has an immune response to
the HIV vaccine that is measured just after
randomization/vaccination. The placebo volunteers who
remain uninfected are vaccinated at the end of the study and
immune response is measured then. Bold numbers are directly
observed, italicized numbers are inferred. Randomization
assures that roughly 100 placebo patients would be in each
quartile, as occurred in the vaccine group. In this example,
consistent with the association hypothesis, the vaccine has no
overall eﬀect but identiﬁes patients with an intrinsic ability to
avoid infection.
Quartile of antibody response
following HIV vaccination
Group 1st 2nd 3rd 4th Total
Vaccine
Total 100 100 100 100 400
Infected 30 15 10 5 60
Uninfected 70 85 90 95 340
Placebo
Total ±100 ±100 ±100 ±100 400
Infected ±29 ±16 ±9 ±4 58
Uninfected 71 84 91 96 342
We call this closeout placebo vaccination (CPV). Table 3 pro-
vides hypothetical data illustrating how CPV can be used to
suggest that X0 is associated with constitutional ability to
remain uninfected, but has no causative role.
Figure 1 and Table 3 are meant to informally illustrate
how to infer X0 in the placebo group. In the sequel, we
develop formal methods that rely on the thinking of coun-
terfactuals, causal inference, and principal stratiﬁcation. We
also describe some simple methods, investigate performance
of diﬀerent methods by simulation, and discuss some more
elaborate approaches.
2. Model-Based Approach
Suppose that n patients per group are randomized to placebo
or vaccine. Prior to randomization, all patients receive a ra-
bies vaccine and the immune response to rabies vaccine (W0)
is measured before randomization. Patients are then random-
ized to either a placebo or HIV vaccine injection and shortly
thereafter, immune response to the HIV vaccine (X0) is mea-
sured in the vaccine group. At the closeout or end of the
trial, all uninfected placebo recipients receive the HIV vac-
cine and shortly thereafter, immune response to this vaccine
is measured (XC). Let Y be the infection indicator and Z be
the vaccine indicator. A schematic representation of a vaccine
trial augmented with BIV and CPV is given in Figure 2.
Our approach to using these data is perhaps best de-
scribed using counterfactual reasoning (Rubin, 1974, 1977,
1978; Halloran and Struchiner, 1995) and principal strati-
ﬁcation (Frangakis and Rubin, 2002). First, let W0i be the
baseline rabies-speciﬁc adaptive immune response for patient
i. This is seen in everyone. The response to HIV vaccina-
tion is diﬀerent. One can write X0i(z) as the (post) baseline
HIV-speciﬁc immune response to HIV vaccination. We call
hX
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Figure 2. Schematic representation of augmented de-
signs. Circles and lowercase letters denote inoculations,
immuneresponse is denoted by capital letters. Under a tradi-
tional design, patients are vaccinated either with HIV vaccine
(h) or placebo (p) and immune response to the HIV vaccine
(X = X0) is measured shortly thereafter in the vaccine group.
Under BIV, both groups are vaccinated against rabies (r) and
the immune response to rabies vaccine (W = W 0) is measured
prior to randomization. Under CPV, placebo patients who are
uninfected at the end of the trial receive HIV vaccine at close-
out and their immune response is measured then (X = XC).
X0i(0), X0i(1) potential covariates; X0i(1) is measured in vac-
cine recipients while X0i(0) would be 0 in nearly everyone.
We say that X0i(1) is realized in the vaccine group and unreal-
ized in the placebo group. Using the terminology of Frangakis
and Rubin (2002), Xi(1) = x, Xi(0) = 0 deﬁnes a principal
stratum indexed by x. Principal strata are a classiﬁcation of
subjects deﬁned by the potential values of a post-treatment
variable under each of the treatments being considered.
They also call X0(1) a principal surrogate and distinguish it
from a “statistical” surrogate, which for our setup would be
Xobs = X0(1)Z + X0(0) (1 − Z). We next deﬁne Yi(z) as the
outcome for person i following treatment z. We call the pair
Yi(0), Yi(1) potential outcomes. We also deﬁne XCi(z, y)a s
the closeout HIV-speciﬁc adaptive immune response for per-
son i when given treatment z and following outcome y. Only
XCi(0, 0) is measured and meaningful:
We make the following simplifying assumptions:
 All patients receive the assigned injections so there is no
noncompliance.
 There are no missing data; W0, Y0 are measured on ev-
eryone, X0 is measured on all vaccinees, and XC is mea-
sured on all placebo uninfecteds.
 No infections occur between the time of randomization
and when X0 is measured, say the interval [0, m].1164 Biometrics, December 2006
The ﬁrst two are for simplicity and can be relaxed. For exam-
ple, if there is some noncompliance but it is governed by an
independent random mechanism, our methods could be ap-
plied to just the compliers. With data missing completely at
random the methods can be applied directly to the observed
data. If the data are missing at random, methods that in-
corporate covariates associated with missingness can be used.
The last assumption is more likely to be met if m is small.
If a few infections occur in [0, m], an analysis that throws
them out may be acceptable. We discuss how to modify our
approach to incorporate infections during [0, m] in Section 6.
We next specify probit models for the eﬀect of the “baseline
covariate” X0(1) on the probability of infection in both groups:
pz(x)=P{Yi(z)=1|Zi = z,X0i(1) = x}
=Φ ( β0 + β1z + β2x + β3zx), (1)
where Φ() is the standard normal c.d.f. (cumulative distribu-
tion function). This equation speciﬁes a model for a standard
covariate by treatment interaction for a clinical trial. The pro-
bit is handy because it is easy to integrate over x, which we
will need to do later. Note that (1) assumes that W0 has no
eﬀect on Y(z) once X0(1) and Z are in the model. This can
also be relaxed, as we discuss in Section 5.
Diﬀerent causal estimands can be used to quantify the eﬀect
of the vaccine as a function of X0(1). For example, following
Hudgens and Halloran (2004) we deﬁne vaccine eﬃcacy as
1 −
E{Yi(1)|X0i(1) = x}
E{Yi(0)|X0i(1) = x}
= VE(x)
=1−
Φ{β0 + β1 +( β2 + β3)x}
Φ(β0 + β2x)
.
With our probit model, a natural estimand is
Φ
−1[E{Yi(1)|X0i(1) = x}] − Φ
−1[E{Yi(0)|X0i(1) = x}]
=Δ P(x)=β1 + β3x.
Note that when β3 =0 ,Δ P(x) is free of x, this is not true for
VE(x).
If X0i(1) were observed in everyone, estimation would be
straightforward. As X0i(1) is not observed in the placebo
group, we require at least one of the following two assump-
tions to proceed:
 X0i(1) can be viewed as a baseline covariate or
{X0i(1)|W0i,Z=0 }
D = {X0i(1)|W0i,Z=1 }.
 For placebo uninfecteds, X0i(1) = xi + U1 and
XCi(0, 0) = xi + U2 where U1 and U2 are i.i.d. (indepen-
dent and identically distributed) mean 0. We call this
time constancy of immune response.
The ﬁrst assumption is true by design in randomized trials
and allows us to impute X0i(1) based on W0i in the placebo
group. While technically measured post-randomization, this
“post-baseline” covariate can be used as a baseline covari-
ate. The second assumption allows us to replace X0i(1) with
XCi(0, 0) as a covariate in the probit model for placebo un-
infecteds. Under the model X = x + U, one can think of x as
the true time constant immune response, which is observed
subject to measurement error and our interest focuses on the
regression of Y on X. This assumption cannot be accepted
uncritically as immune response can diminish with age, such
as for herpes zoster, if the trial is long enough. Addition-
ally, volunteers might get subinfectious exposures to a virus
that modiﬁes immune response. This is thought possible for
HIV where commercial sex workers showed immune responses
to HIV but remained uninfected. However even here, the as-
sumption might hold if the immune response is eﬀectively
primed by subinfectious exposure pre-baseline and this re-
sponse is maintained during the course of the trial. Addition-
ally, this assumption can be examined, as we will discuss in
Section 5.
Our ﬁnal assumption allows us to easily integrate over the
distribution of X0(1)|W0:
 The distribution of X0(1), W 0 is bivariate normal with
moments μx, μw, σ2
x, σ2
w, ρ.
This assumption can also be relaxed but the integration would
be more complicated.
To estimate β =( β0,β 1,β 2,β 3), we use maximum likeli-
hood. We begin by constructing a likelihood incorporating
both BIV and CPV. The likelihood contribution for vaccinees
is simple,
 
i∈V
p1(x0i)
yi{1 − p1(x0i)}
1−yi,
where V is the set of vaccinees. For uninfected placebo volun-
teers we use XCi in lieu of X0i and their contribution is
 
i∈P(U)
{1 − p0(xCi)}
1−yi,
where P(U) is the set of uninfected placebo recipients. In the
placebo infecteds, X0(1) is missing and we need to integrate
p0(X0(1)) over the distribution of X0(1)|W0 to obtain their
likelihood contribution. Under our last assumption, it follows
that X0(1)|W0 = w is normal with mean μ∗(w0)=μx +
ρσx/σw(w0 − μw) and variance σ2
∗ = σ2
x(1 − ρ2). The (inte-
grated) probability of infection for a person with W 0 = w0 is
thus
p
∗
0(w0)=E[Φ{β0 + β2X0(1)}]=Φ
 
β0 + β2μ∗(w0)
 
1+( β2σ∗)2
 
.
The right-hand side obtains the result that E[Φ(a + U)] =
Φ{(a + μ)/
√
1+σ2} for U normal(μ, σ2). The overall likeli-
hood is thus
LBC(β)=
 
 
i∈V
p1(x0i)
yi{1 − p1(x0i)}
1−yi
 
×
⎡
⎣
 
i∈P(U)
{1 − p0(xCi)}
⎤
⎦
⎧
⎨
⎩
 
i∈P(I)
p
∗
0(w0i)
⎫
⎬
⎭
.
Note that p∗
0(w0i) depends on the moments of X0(1), W 0,
which are unknown. We advocate estimating these moments
using vaccine group data and regard them as ﬁxed in LBC.
Because of this, the standard error estimates obtained by
the Fisher information matrix are incorrect and we suggestAugmented Designs to Assess Immune Response in Vaccine Trials 1165
using the nonparametric bootstrap method to obtain stan-
dard errors.
We can also construct likelihoods based on augmenting
the usual design with BIV alone or CPV alone. These are,
respectively,
LB(β)=
 
 
i∈V
p0(x0i)
yi{1 − p0(x0i)}
1−yi
 
×
 
 
i∈P
p
∗
0(w0i)
yi 
1 − p
∗
0(w0i)
 1−yi
 
,
where P is the set of placebo recipients, and
LC(β)=
 
 
i∈V
p0(x0i)
yi{1 − p0(x0i)}
1−yi
 
×
⎡
⎣
 
i∈P(U)
{1 − p0(xCi)}
⎤
⎦Φ
 
β0 + β2μx  
1+( β2σx)2
 #P(I)
,
where #P(I) is the number of placebo infecteds. The last
Φ() in LC(β) is just the probability that a generic placebo
patient is infected and equals E{β0 + β1X0(1)}, where X0(1)
is normal (μx, σ2
x). Based on the estimated β’s it is a simple
matter to plug them into a causal estimand. Standard errors
and conﬁdence intervals for causal estimands can be computed
from the bootstrap.
3. Closeout Placebo Vaccination Alone
The previous section outlined how BIV and CPV can be used
to estimate the eﬀect of immune response using a model and
likelihood. In this section, we show how closeout placebo vac-
cination by itself can be used without a model to assess im-
mune response. The approach is inspired by Tables 1 and 2
and Gilbert, Bosch, and Hudgens (2003).
Denote by f0(x) and f1(x) the densities of X0(1) for the
placebo and vaccine groups, respectively. In each group we can
decompose the distribution of immune response into a mixture
of those who would/did become infected and those who would
not/did not. Thus we can write the immune response densities
in mixture form,
f0(x)=f0(x|Y =1 ) θ0 + f0(x|Y = 0)(1 − θ0), and (2)
f1(x)=f1(x|Y =1 ) θ1 + f1(x|Y = 0)(1 − θ1), (3)
where θ  is the true proportion of infected volunteers in group
 . In the vaccine group the mixed density and the two con-
stituent densities are directly estimable as is θ1. In the placebo
group θ0 and f0(x|Y = 0) are directly estimable, provided
{X0(1)|Y =0 }
D =( XC |Y = 0). To get f0(x|Y =1 )w er e -
place f0(x) with f1(x) and solve by subtraction.
With these arguments and Bayes’ theorem, one can deduce
that
p0(Y =1|x)=θ0
f0(x|Y =1 )
f1(x)
, and (4)
p1(Y =1|x)=θ1
f1(x|Y =1 )
f1(x)
. (5)
The terms on the right-hand side can be estimated nonpara-
metrically and thus so can the left-hand side.
Interestingly, the diﬀerent conditional distributions of
X0(1) can be compared to test the role of X0(1). To moti-
vate these tests, consider Table 3. Suppose the counts in the
placebo uninfected row were very similar over the four quar-
tiles. This would suggest that unrealized potential immune re-
sponse was unassociated with infection risk. Using the fact
that f1(x)=f0(x), the continuous analog to see whether
the counts in the placebo uninfected row are similar can be
written as
H
2
0 :f0(x|Y =0 )=f1(x) ⇐⇒ p0(Y =1|x)=θ0.
Note that if the probit model (1) is correct, then H2
0 is equiva-
lent to β2 = 0. Also note that H2
0 corresponds to the causation
hypothesis that was suggested to explain Tables 1 and 2.
At the other extreme, suppose that the counts in the vac-
cine uninfected row were quite similar to the counts in the
placebo uninfected row. This would suggest that immune re-
sponse has no causative eﬀect on infection. The continuous
analog is
H
3
0 :f0(x|Y =0 )=f1(x|Y =0 )
⇐⇒ p0(Y =0|x) ∝ p1(Y =0|x).
Unlike H2
0,H 3
0 does not correspond to β3 = 0 even if (1) is
correct, unless β1 = 0. Note that H3
0 corresponds to the asso-
ciation hypothesis suggested to explain Tables 1 and 2.
Diﬀerent methods could be used to test equality of the den-
sities speciﬁed by H2
0 and H3
0 such as t-tests, rank tests, or
Kolmogorov-type tests. For a t-test of H2
0, one compares all
X0i(1)’s in the vaccine group to the XCi’s of the placebo un-
infecteds. For a t-test of H3
0, one compares the X0i(1)’s of the
vaccine uninfecteds to the XCi’s of the placebo uninfecteds.
4. Simulation
To assess these designs, we conducted a simulation under the
model assumptions given in the previous section. We gener-
ated data where P{Y (z)=1|Z = z, X0(1) = x} is given by
(1), and W 0, X0(1) are bivariate Gaussian with correlation ρ.
We set E[p0{X0(1)}]=θ0 = 0.10 and θ1 = 0.08. We selected
β2, β3 in terms of relative risk,
p {Q(7/8)}
p {Q(1/8)}
= R ,
where Q(7/8), Q(1/8) are the seventh and ﬁrst octiles of the
distribution of X0(1). Three scenarios were considered, chosen
with the hazards of Tables 1 and 2 in mind:
 Association: Here R1 = R0 = 0.2, β3 = 0, and ΔP(x)i s
free of x.
 Causation: Here R0 =1 ,R1 = 0.2, β2 = 0, and ΔP(x)
depends on x.
 Both: Here R0 = 0.33, R1 = 0.11, βk < 0, k =0 ,1 ,a n d
ΔP(x) depends on x.
For each simulated data set maximum likelihood using LBC,
LB, and LC was used to estimate β. We also constructed a pro-
bit likelihood based on observing X0(1) exactly in everyone.
Estimates based on this likelihood correspond to an unattain-
able benchmark.1166 Biometrics, December 2006
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Figure 3. Sample variance of estimates of β divided by the
sample variance when the X0(1) is used. Estimates denoted by
B, C,2 ,a n dX correspond to designs using BIV alone, CPV
alone, BIV + CPV, and the impossible benchmark where
X0(1) is known in everyone, respectively. For BIV alone when
ρ = 0.25 the relative sample variance is enormous and oﬀ the
chart for the Association scenario. One can extrapolate the
behavior of the designs using CPV alone and the benchmark
ρ = 0 as their behavior is free of ρ. Each symbol is based on
10,000 simulated trials.
The ﬁrst set of simulations used 10,000 replications and
varied by 0.25, 0.5, 0.75, 1. We do not evaluate ρ = 0 as the
model using BIV alone is unidentiﬁable. Replications were not
tallied when convergence was not attained, which was very
rare except for BIV alone with ρ = 0.25 when the estimates
did not converge 2–3% of the time.
Figure 3 provides the sample variance for the four estimates
of β, divided by the sample variance when X0(1) is used, as a
function of ρ under the Association and Causation scenarios.
Relative behavior of the diﬀerent estimates is similar under
the Both scenario and hence not reported. For the estimates
using CPV (C) alone or the benchmark (X), the sampling
variability is free of ρ. The sample variance with CPV alone
is from nearly 10 times to almost 25 times larger than with the
benchmark. The performance of BIV (B) alone depends pro-
foundly on ρ with ρ = 0.25 exhibiting extremely large sample
variances for the Association scenario, and variances similar
to CPV alone for the Causation scenario. For ρ>0.5, BIV
and CPV + BIV have similar variance ratios. We see that
for large ρ CPV is unnecessary and for small ρ BIV performs
poorly. As ρ = 0.25, both CPV and BIV are helpful.
Our second set of simulations evaluates power and is given
in Table 4 with n = 1000 or 2500, ρ = 0.25 or 0.50, for the
three scenarios Association, Causation, and Both. For the
Wald tests, a nonparametric bootstrap standard error was
calculated using the sample variance of 100 bootstrap resam-
ples for each simulated trial. Resamples where convergence
was not attained were thrown out, which was rare except for
BIV alone with ρ = 0.25. As before, BIV alone with ρ = 0.25
had problems with convergence and these were exacerbated
in the bootstrap resamples.
We begin by evaluating the Wald test. First, the benchmark
has extremely high power, except for β3 under scenario B
with n = 1000. For CPV + BIV, power is generally good to
excellent for all scenarios with n = 2500. For n = 1000, power
is degraded, especially with ρ = 0.25. For BIV alone, power
is similar to CPV + BIV for ρ = 0.50 and much worse for
ρ = 0.25. Generally, power for CPV alone is much worse than
for BIV alone with ρ = 0.50 and moderately better with ρ =
0.25. The power of the t-tests is usually similar to CPV alone
and close to at least 0.50 for scenarios A and C with n = 2500.
We also did a few limited simulations to address speciﬁc
issues. In practice, one might want to perform CPV on a frac-
tion of the placebo uninfecteds. For scenario A, we compared
the estimates using CPV alone, where XC was obtained in
everyone to where it was obtained in 1/2, 1/4, or 1/10 of the
placebo uninfecteds. The sampling variance for either ˆ β2 or ˆ β3
was about 60%, 300%, and 1000% larger than when XC was
obtained in everyone, respectively. Second, we evaluated the
procedures when the moments were set to their true values
and not estimated. The sampling variance for CPV alone and
for BIV alone was nearly halved when true values were used
instead of estimated values. For CPV + BIV, the sampling
variability was only modestly reduced. For larger trials, for
example, n = 8000 with low event rates, the performance of
CPV and BIV relative to BIV + CPV might be better than
shown in Figure 3 and Table 4 as the estimated moments of
X0(1), W 0 would be more reliable. It also suggests that one
might want to consider use of a full likelihood. For example,
for CPV alone uses
L
 
β,μ x,σ
2
x
 
= LC(β)
 
i∈V
φ
 
xi0;μx,σ
2
x
   
i∈P(U)
f0
 
xiC
 
 Yi =0 ;μx,σ
2
x
 
,
where φ(x; μ, σ2) is the normal density and f0(xiC |Yi =0 ;
μx, σ2
x) is the density for uninfecteds, derived under (1) and
a Gaussian model for X0(1).
In summary, the new designs can be eﬃcient and powerful
even with n = 1000 if ρ>0.5. If ρ is modest, a larger sample
size is required to achieve strong power as CPV is necessary.
If ρ is large enough, CPV may be unnecessary, while if ρ is
too small, BIV alone may be useless. With n = 2500 we have
excellent power for scenarios A and C with ρ = 0.5 using
BIV alone and good to excellent power with the BIV + CPV
combination with ρ = 0.25. Even with CPV alone, power is
greater than 50% for these two scenarios. This conﬁguration is
not unlike VAX004 suggesting augmented designs could have
helped inform the debate about these two hypotheses. It is
clear that the performance of the designs depends dramat-
ically on speciﬁc scenarios. In practice, careful analysis ofAugmented Designs to Assess Immune Response in Vaccine Trials 1167
Table 4
Simulated power for Wald and t-test of H2
0 and H3
0 under various augmented designs. The Wald tests for the X0 design is
when the actual X0 is used in (1) and thus serves as an unattainable benchmark. The t-test compares the XCi’s from the
placebo uninfecteds to the X0i of the vaccine (vaccine uninfecteds) to test H2
0 (H3
0). Standard errors for Wald tests are
based on a bootstrap standard error with 100 bootstrap resamples. Power exceeding 80% is bolded. Each line is based on
1000 simulated vaccine trials.
Test of H2
0 or β2 = 0 Test of H3
0 or β3 =0
Wald tests Wald tests t-test t-test
n ρ Scenario CPV CPV BIV CPV + BIV X0 CPV CPV BIV CPV + BIV X0
1000 0.25 A 0.34 0.40 0.01 0.58 1.0 0.06 0.04 0.03 0.04 0.05
0.50 A 0.35 0.40 0.86 0.91 1.0 0.06 0.05 0.03 0.04 0.05
0.25 C 0.07 0.08 0.00 0.06 0.04 0.23 0.30 0.13 0.43 0.98
0.50 C 0.06 0.06 0.04 0.04 0.05 0.24 0.30 0.78 0.78 0.99
0.25 B 0.19 0.22 0.00 0.32 0.99 0.09 0.17 0.11 0.22 0.66
0.50 B 0.20 0.23 0.57 0.64 0.99 0.08 0.16 0.35 0.40 0.71
2500 0.25 A 0.70 0.74 0.38 0.91 1.0 0.07 0.05 0.03 0.05 0.05
0.50 A 0.68 0.74 1.0 0.99 1.0 0.07 0.05 0.05 0.06 0.05
0.25 C 0.06 0.07 0.02 0.05 0.040 0.47 0.52 0.63 0.78 1.0
0.50 C 0.05 0.07 0.05 0.06 0.050 0.48 0.52 0.99 0.99 1.0
0.25 B 0.39 0.44 0.22 0.64 1.0 0.12 0.31 0.30 0.46 0.97
0.50 B 0.43 0.48 0.95 0.97 1.0 0.11 0.28 0.65 0.71 0.97
performance would be required to settle on a speciﬁc aug-
mented design.
We note that a correlation of close to 0.5 may be a realistic
aspiration. In the VAX004 trial, the vaccine consisted of two
strains of viral gp-120, which is a sequence of 120 amino acids
that comprise the outer envelope of the virus. The two strains
were denoted MN and GNE8. Two nonoverlapping regions of
the envelope, prone to mutations, are called the V2 and V3
loops. The amino acid sequences for the V2 loop and the
V3 loop of the gp120 are completely diﬀerent and thus the
immune response induced by these two diﬀerent loops should
behave like responses to irrelevant vaccinations. Correlations
between these loops were 0.42 and 0.44, respectively, for the
MN and GNE8 strains. Correlations across strains were 0.34
and 0.48 (Figure 3 of Gilbert et al., 2005).
5. Elaborations
The methods of this article can help decide whether an im-
proved vaccine is worth evaluating in a phase III trial. Suppose
that after tinkering with the old vaccine, a new version was
created, which shifted the distribution of the immune response
to the right by Δ. So in an obvious notation, we have X0(1)old
with moments μx and σ2
x, while X0(1)new has moments μx +
Δ and σ2
x. We assume that a person with response x under
the old vaccine is infected with probability
Φ{β0 + β1 + β2x + β3(x +Δ ) }
under the new vaccine. Note that Δ is missing from β2 as only
β3 reﬂects the causative eﬀect of immune response. Overall,
we calculate the expected event rate with the new vaccine
θ
new
1 =
 
Φ{β0 + β1 + β2x + β3(x +Δ ) }φ
 
x
 
 μx,σ
2
x
 
dx.
Based on the data from the trial of the old vaccine, one can es-
timate θ0 and θnew
1 and then estimate the sample size required
for a phase III trial of the new vaccine with improved immune
response Δ. Or one might conclude that θnew
1 is too modest to
proceed.
Closeout placebo vaccination requires time constancy of im-
mune response. One way to examine this assumption would be
to close out some fraction of the placebo uninfecteds midway
through the trial, vaccinate them, and obtain their immune
response, say XC/2. Equality of the distributions of XC/2 and
XC supports time constancy of immune response provided the
eﬀect of X0(1) on Y does not vary with time. To formalize this,
let YC/2, YC be the infection indicators over half the trial and
the entire trial, respectively. If
p0{YC/2 =1|X0(1)}∝p0{YC =1|X0(1)} (6)
then
H
T2
0 :XC/2
D = XC
is consistent with time constancy of immune response on an
individual level. Note that if (6) does not hold, there is no
point in examining HT2
0 .
Testing HT2
0 need not be very costly. Simple power
calculations show that for a 8800 person trial with 90% power
to detect a 10% versus 8% diﬀerence in infection rates, re-
moving 10% of placebo uninfecteds halfway through would
retain at least 88% power. Additionally, comparing XC/2 in
440 “halfway” placebo uninfecteds to XC in say the 3520 ﬁnal
placebo uninfecteds would give 97% power to detect a stan-
dardized diﬀerence (mean diﬀerence over standard deviation)
of 0.20.
Another way to examine time constancy of immune re-
sponse is to see whether the relationships between W 0, X0(1)
and W 0, XC are the same in the two arms. But this also re-
quires assumptions. For example, if the following probit model
holds
P{Y =1|W0,X 0(1),Z} =Φ {β0 + β1Z + β2X0(1)}, (7)1168 Biometrics, December 2006
then
H
TW
0 :{X0(1),W 0 |Y =0 ,Z=1 }
D =( XC,W 0 |Y =0 ,Z=0 )
is consistent with time constancy of immune response. Note
that H
TW
0 can be tested using data readily available from a
CPV trial and does not require a partial closeout halfway
through the trial.
Model (1) assumes that there is no eﬀect of W0 on infection
risk once X0(1) is in the model. One can specify generaliza-
tions to (1) that include W0 as an additional main eﬀect, or
even allow for interaction with treatment,
P{Y =1|X0(1),Z,W 0} =Φ {β0 + β1Z + β2X0(1) + β3W0
+β4ZX0(1) + β5ZW0}, (8)
and likelihood construction for this model would parallel con-
struction based on (1). It is perhaps surprising that even for
our setting, where X0(1) is missing in the placebo group, this
model with two interactions can be estimated provided CPV
is performed. If CPV is not done, (8) is identiﬁable provided,
for example, β5 = 0. With CPV one could test whether β5
and/or β3 were 0. However, such tests would likely have poor
power, as trials are powered for a treatment main eﬀect and
estimating two interactions may be diﬃcult.
In principle, W0 could be any baseline variable correlated
with X0(1) and a baseline irrelevant vaccination need not be
performed. Presumably, however, W0 based on BIV should
have a much stronger relationship with X0(1) than a variable
such as race, gender, or age. An additional issue with nonim-
munologically based W0 is the perhaps greater concern that
β3 and or β5 in (8) might not be zero. It is important to realize
that if (8) holds with (β3, β5)  = (0, 0) then inference derived
from ﬁtting (the incorrect) model (1) would be misleading.
We made a simplifying assumption that there were no in-
fections in either group until X0(1) was measured. If infections
do occur over the interval [0, m] we can still obtain consistent
estimates of the parameters provided we derive a likelihood
under more assumptions. We illustrate one way. Consider a
BIV design. Because the likelihoods in Section 2 factor L(β)=
Lv(β0 + β1,β 2 + β3)Lp(β0,β 2) we can estimate β0, β2 using
Lp(), given consistent estimates of θ =( μx,μ z,σ2
x,σ2
z,ρ) (re-
call that Lp depends implicitly on θ). For the vaccine group,
let V(m) be the set of vaccinees who become infected over the
interval [0, m] and V(R) be the rest of the vaccinees. Then
under assumption (6) applied over [0, m], the likelihood for
the vaccine group is proportional to
⎡
⎣
 
i∈V(R)
p1(x0i)
yi{1 − p1(x0i)}
1−yiφ(x0i,w 0i;θ)
⎤
⎦
×
⎧
⎨
⎩
 
i∈V(m)
 
p1(u)
yiφ(u,w0i;θ)du
⎫
⎬
⎭
,
where φ is the bivariate normal density function.
6. Final Comments
While this article has focused on immune response to an HIV
vaccine, it is clear that the methods would apply to any vac-
cine trial. Chan et al. (2003) describe the role of immune
response in vaccine development and point out the diﬃculty
of establishing immune response as a surrogate for protection
or disease burden as immune response is only measured in the
vaccine group. The designs of this article allow one to use the
principal surrogacy approach of Frangakis and Rubin (2002).
This article has focused on evaluating the eﬀect of im-
mune response on preventing infections. Current thinking on
HIV vaccines is that they may have their major eﬀect on
post-infection outcomes, such as the viral load setpoint, the
steady-state amount of virus in the bloodstream shortly after
infection. The approach of this article could also be applied to
post-infection endpoints, though this is necessarily more as-
sumption dependent as the infected groups are not balanced
by virtue of randomization (see Gilbert et al., 2003; Hudgens,
Hoering, and Self, 2003).
The simulations show the profound dependence of these
methods on ρ. Fortunately, ρ can be estimated well before
closeout. However, even if ρ is large, there is some beneﬁt
in obtaining some CPV data as they provide a check of the
imputation-based W0 alone. Additionally, if it turns out to
be an unanticipated immune response to the HIV vaccine,
say X0(1)u is strongly associated with infections and W0 is
independent of X0(1)u, a BIV-alone design would have been
a mistake. CPV oﬀers protection against this possibility. Fi-
nally, a simple t-test based on CPV data alone is appealing
for its simplicity and transparency. Of course, CPV requires
the strong assumption of time constancy of immune response.
In practice, several vaccinations over several months may
be necessary during which time infections might accrue and
the immune responses might wax and wane in conjunction
with the vaccinations so thought is required to choose a pre-
cise time to measure X0(1). Another approach would be to
develop methods that explicitly model the time-varying na-
ture of X0(1) and use time to infection as the outcome rather
than a binary indicator of infection.
Implementation of these designs could be done in an in-
cremental fashion. Initially, small studies could be conducted
to establish the extent of correlation between W0 and X0(1),
which irrelevant vaccine was most useful, and whether time
constancy of immune response were plausible. If promising, an
adaptive augmented phase III design could then be initiated.
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